Literature DB >> 17762778

Preerythrocytic malaria vaccine development.

Sebastian A Mikolajczak1, Ahmed S I Aly, Stefan H I Kappe.   

Abstract

PURPOSE OF REVIEW: This review examines the potential of current preerythrocytic stage malaria vaccine approaches to reduce the global burden of malaria. RECENT
FINDINGS: Radiation-attenuated parasite vaccines induce lasting sterile protection in all models tested. Inherent safety concerns in conjunction with challenges to produce and deliver a radiation-attenuated parasite vaccine have prevented its mass production and application. Recent advances in genetic engineering and initiatives in production process development of live attenuated malaria vaccines, however, will overcome roadblocks that currently prevent their large-scale application. Development of preerythrocytic subunit vaccines has focused on the circumsporozoite protein and the thrombospondin related anonymous protein, yet the most advanced circumsporozoite protein-based vaccine confers limited protection against infection in malaria endemic areas. Work in rodent malaria models demonstrated that circumsporozoite protein-based immunity is not required for to achieve sterile protection.
SUMMARY: We conclude that preerythrocytic malaria vaccine efforts should focus on two major areas: development of a safe live attenuated sporozoite vaccine with its accelerated testing in malaria endemic areas and identification of as yet unknown antigens that reproduce sterilizing immune responses induced by vaccination with whole parasites. The sporozoite challenge model provides a unique opportunity to rapidly test preerythrocytic vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17762778     DOI: 10.1097/QCO.0b013e3282ef6172

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  14 in total

1.  Development of the malaria parasite in the skin of the mammalian host.

Authors:  Pascale Gueirard; Joana Tavares; Sabine Thiberge; Florence Bernex; Tomoko Ishino; Genevieve Milon; Blandine Franke-Fayard; Chris J Janse; Robert Ménard; Rogerio Amino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Naturally acquired IgG antibodies against the C-terminal part of Plasmodium falciparum sporozoite threonine-asparagine-rich protein in a low endemic area.

Authors:  Chittakun Suwancharoen; Chaturong Putaporntip; Thanaporn Rungruang; Somchai Jongwutiwes
Journal:  Parasitol Res       Date:  2011-02-01       Impact factor: 2.289

Review 3.  Antigens for pre-erythrocytic malaria vaccines: building on success.

Authors:  C Speake; P E Duffy
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

Review 4.  Malaria parasite development in the mosquito and infection of the mammalian host.

Authors:  Ahmed S I Aly; Ashley M Vaughan; Stefan H I Kappe
Journal:  Annu Rev Microbiol       Date:  2009       Impact factor: 15.500

5.  Immunogenicity, protective efficacy and safety of a recombinant DNA vaccine encoding truncated Plasmodium yoelii sporozoite asparagine-rich protein 1 (PySAP1).

Authors:  Jia Zhao; Shu Deng; Jiayuan Liang; Yaming Cao; Jun Liu; Feng Du; Hong Shang; Liwang Cui; Enjie Luo
Journal:  Hum Vaccin Immunother       Date:  2013-01-28       Impact factor: 3.452

6.  HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.

Authors:  Charlotte V Hobbs; Tatiana Voza; Alida Coppi; Brian Kirmse; Kennan Marsh; William Borkowsky; Photini Sinnis
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

Review 7.  Malaria parasite pre-erythrocytic stage infection: gliding and hiding.

Authors:  Ashley M Vaughan; Ahmed S I Aly; Stefan H I Kappe
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

Review 8.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

9.  Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection.

Authors:  Ahmed S I Aly; Sebastian A Mikolajczak; Hilda Silva Rivera; Nelly Camargo; Vanessa Jacobs-Lorena; Mehdi Labaied; Isabelle Coppens; Stefan H I Kappe
Journal:  Mol Microbiol       Date:  2008-05-05       Impact factor: 3.501

10.  A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites.

Authors:  Marjorie Mauduit; Anne Charlotte Grüner; Rita Tewari; Nadya Depinay; Michèle Kayibanda; Jean-Marc Chavatte; Jean-François Franetich; Andrea Crisanti; Dominique Mazier; Georges Snounou; Laurent Rénia
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.